Imaging and biopsy of HIV-infected individuals undergoing analytic treatment interruption

Chuen-Yen Lau, Matthew A Adan, Jessica Earhart, Cassie Seamon, Thuy Nguyen, Ariana Savramis, Lindsey Adams, Mary-Elizabeth Zipparo, Erin Madeen, Kristi Huik, Zehava Grossman, Benjamin Chimukangara, Wahyu Nawang Wulan, Corina Millo, Avindra Nath, Bryan R Smith, Ana M Ortega-Villa, Michael Proschan, Bradford J Wood, Dima A Hammoud, Frank Maldarelli, Chuen-Yen Lau, Matthew A Adan, Jessica Earhart, Cassie Seamon, Thuy Nguyen, Ariana Savramis, Lindsey Adams, Mary-Elizabeth Zipparo, Erin Madeen, Kristi Huik, Zehava Grossman, Benjamin Chimukangara, Wahyu Nawang Wulan, Corina Millo, Avindra Nath, Bryan R Smith, Ana M Ortega-Villa, Michael Proschan, Bradford J Wood, Dima A Hammoud, Frank Maldarelli

Abstract

Background: HIV persistence during antiretroviral therapy (ART) is the principal obstacle to cure. Lymphoid tissue is a compartment for HIV, but mechanisms of persistence during ART and viral rebound when ART is interrupted are inadequately understood. Metabolic activity in lymphoid tissue of patients on long-term ART is relatively low, and increases when ART is stopped. Increases in metabolic activity can be detected by 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and may represent sites of HIV replication or immune activation in response to HIV replication.

Methods: FDG-PET imaging will be used to identify areas of high and low metabolic uptake in lymphoid tissue of individuals undergoing long-term ART. Baseline tissue samples will be collected. Participants will then be randomized 1:1 to continue or interrupt ART via analytic treatment interruption (ATI). Image-guided biopsy will be repeated 10 days after ATI initiation. After ART restart criteria are met, image-guided biopsy will be repeated once viral suppression is re-achieved. Participants who continued ART will have a second FDG-PET and biopsies 12-16 weeks after the first. Genetic characteristics of HIV populations in areas of high and low FDG uptake will be assesed. Optional assessments of non-lymphoid anatomic compartments may be performed to evaluate HIV populations in distinct anatomic compartments.

Anticipated results: We anticipate that PET standardized uptake values (SUV) will correlate with HIV viral RNA in biopsies of those regions and that lymph nodes with high SUV will have more viral RNA than those with low SUV within a patient. Individuals who undergo ATI are expected to have diverse viral populations upon viral rebound in lymphoid tissue. HIV populations in tissues may initially be phylogenetically diverse after ATI, with emergence of dominant viral species (clone) over time in plasma. Dominant viral species may represent the same HIV population seen before ATI.

Discussion: This study will allow us to explore utility of PET for identification of HIV infected cells and determine whether high FDG uptake respresents areas of HIV replication, immune activation or both. We will also characterize HIV infected cell populations in different anatomic locations. The protocol will represent a platform to investigate persistence and agents that may target HIV populations.

Study protocol registration: Identifier: NCT05419024.

Keywords: HIV; HIV persistence; PET/CT; biopsy; clinical trial; reservoir; treatment interruption.

Conflict of interest statement

Author BW would like to disclose the following: Licensed Patents/Royalties: Philips and NIH have a patent licensing agreement under which NIH receives royalties, a portion of which are then given to BW. NVIDIA and NIH have a licensing agreement. NIH and Canon have a licensing agreement. BW is Principal Investigator on the following Cooperative Research & Development Agreements (CRADAs), between NIH and industry: Philips (CRADA), Philips Research (CRADA), Celsion Corp (CRADA), BTG Biocompatibles/Boston Scientific (CRADA), Siemens (CRADA), NVIDIA (CRADA), XAct Robotics (CRADA). Negotiating CRADA with ProMaxo, Tempus, Galvanize, Theromics, Imactis, Varian. The following industry partners also support research in the Center for Interventional Oncology/Dr. Wood's lab via equipment, personnel, devices and/or drugs: 3T Technologies (devices), Exact Imaging (data), Angiodynamics (equipment), Astra Zeneca (pharmaceuticals, NCI CRADA), ArciTrax (devices and equipment), Imactis (Equipment), Johnson and Johnson (equipment), Medtronic (equipment), Promaxo (equipment & personnel), Theromics (Supplies), Profound (equipment and supplies), and QT Imaging (equipment and supplies). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Lau, Adan, Earhart, Seamon, Nguyen, Savramis, Adams, Zipparo, Madeen, Huik, Grossman, Chimukangara, Wulan, Millo, Nath, Smith, Ortega-Villa, Proschan, Wood, Hammoud and Maldarelli.

Figures

Figure 1
Figure 1
Study schema. ART, antiretroviral therapy; ATI, analytic treatment interruption; VL, viral load. Depicts the overall schema for participant randomization and study procedures. Participants will be randomized 1:1 to continue ART or undergo ATI. ATI participants will undergo a total of three PET/CTs with biopsy, while those who continue ART will receive two PET/CTs with biopsy.

References

    1. Belkhir L, Jonckheere S, Lhommel R, Vandercam B, Yombi JC. High FDG uptake on FDG-PET scan in HIV-1 infected patient with advanced disease. Acta Clin Belg. (2011) 66:419–21. 10.2143/ACB.66.6.2062606
    1. Zanni MV, Toribio M, Robbins GK, Burdo TH, Lu MT, Ishai AE, et al. . Effects of antiretroviral therapy on immune function and arterial inflammation in treatment-naive patients with human immunodeficiency virus infection. JAMA Cardiol. (2016) 1:474–80. 10.1001/jamacardio.2016.0846
    1. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med. (2012) 2(11). 10.1101/cshperspect.a006965
    1. Bronnimann MP, Skinner PJ, Connick E. The B-cell follicle in hiv infection: barrier to a cure. Front Immunol. (2018) 9:20. 10.3389/fimmu.2018.00020
    1. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, et al. . Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis. (2000) 182:1636–42. 10.1086/317615
    1. Riddler SA, Aga E, Bosch RJ, Bastow B, Bedison M, Vagratian D, et al. . Continued slow decay of the residual plasma viremia level in HIV-1-infected adults receiving long-term antiretroviral therapy. J Infect Dis. (2016) 213:556–60. 10.1093/infdis/jiv433
    1. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, et al. . ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. (2007) 3:e46. 10.1371/journal.ppat.0030046
    1. Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O'Shea A, et al. . Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. (2014) 10:e1004010. 10.1371/journal.ppat.1004010
    1. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. . A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature. (2019) 566:120–5. 10.1038/s41586-019-0898-8
    1. Takata H, Kessing C, Sy A, Lima N, Sciumbata J, Mori L, et al. . Modeling HIV-1 latency using primary CD4(+) T cells from virally suppressed HIV-1-infected individuals on antiretroviral therapy. J Virol. (2019) 93:e02248–18. 10.1128/JVI.02248-18
    1. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. (1995) 1:1284–90. 10.1038/nm1295-1284
    1. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. . Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. (1997) 387:183–8. 10.1038/387183a0
    1. Anderson EM, Maldarelli F. The role of integration and clonal expansion in HIV infection: live long and prosper. Retrovirology. (2018) 15:71. 10.1186/s12977-018-0448-8
    1. Halvas EK, Joseph KW, Brandt LD, Guo S, Sobolewski MD, Jacobs JL, et al. . HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. J Clin Invest. (2020) 130:5847–57. 10.1172/JCI138099
    1. Spudich S, Gonzalez-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med. (2012) 2:a007120. 10.1101/cshperspect.a007120
    1. Alexaki A, Wigdahl B. HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog. (2008) 4:e1000215. 10.1371/journal.ppat.1000215
    1. Bull ME, McKernan JL, Styrchak S, Kraft K, Hitti J, Cohn SE, et al. . Phylogenetic analyses comparing HIV sequences from plasma at virologic failure to cervix versus blood sequences from antecedent antiretroviral therapy suppression. AIDS Res Hum Retroviruses. (2019) 35:557–66. 10.1089/aid.2018.0211
    1. Mabvakure BM, Lambson BE, Ramdayal K, Masson L, Kitchin D, Allam M, et al. . Evidence for both intermittent and persistent compartmentalization of HIV-1 in the female genital tract. J Virol. (2019) 93:e00311–19. 10.1128/JVI.00311-19
    1. Kariuki SM, Selhorst P, Anthony C, Matten D, Abrahams M-R, Martin DP, et al. . Compartmentalization and clonal amplification of HIV-1 in the male genital tract characterized using next-generation sequencing. J Virol. (2020) 94:e00229–20. 10.1128/JVI.00229-20
    1. Sorbara LR, Maldarelli F, Chamoun G, Schilling B, Chokekijcahi S, Staudt L, et al. . Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression. J Virol. (1996) 70:7275–9. 10.1128/jvi.70.10.7275-7279.1996
    1. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am. (2001) 39:883–917. 10.1016/S0033-8389(05)70319-5
    1. Pham KH, Ramaswamy MR, Hawkins RA. Advances in positron emission tomography imaging for the GI tract. Gastrointest Endosc. (2002) 55 (7 Suppl):S53–63. 10.1067/mge.2002.124741
    1. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. (2000) 27:683–7. 10.1016/S0969-8051(00)00141-4
    1. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. . FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. (2015) 42:328–54. 10.1007/s00259-014-2961-x
    1. Hammoud DA, Sinharay S, Steinbach S, Wakim PG, Geannopoulos K, Traino K, et al. . Global and regional brain hypometabolism on FDG-PET in treated HIV-infected individuals. Neurology. (2018) 91:e1591–601. 10.1212/WNL.0000000000006398
    1. Sinharay S, Hammoud DA. Brain PET imaging: value for understanding the pathophysiology of HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep. (2019) 16:66–75. 10.1007/s11904-019-00419-8
    1. Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation–current and emerging clinical applications. Clin Radiol. (2015) 70:787–800. 10.1016/j.crad.2015.03.010
    1. Stellingwerff MD, Brouwer E, Lensen KDF, Rutgers A, Arends S, van der Geest KSM, et al. . Different scoring methods of FDG PET/CT in giant cell arteritis: need for standardization. Medicine. (2015) 94:e1542. 10.1097/MD.0000000000001542
    1. McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. . Assessment of total lesion glycolysis by (18)F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. (2017) 23:1981–7. 10.1158/1078-0432.CCR-16-0235
    1. Takahashi MES, Mosci C, Souza EM, Brunetto SQ, Etchebehere E, Santos AO, et al. . Proposal for a quantitative (18)F-FDG PET/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma. Sci Rep. (2019) 9:16429. 10.1038/s41598-019-52740-2
    1. van der Geest KSM, van Sleen Y, Nienhuis P, Sandovici M, Westerdijk N, Glaudemans A, et al. . Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica. Rheumatology. (2021) 61:1072–82. 10.1093/rheumatology/keab483
    1. Yee E, Popuri K, Beg MF, Alzheimer's Disease Neuroimaging I. Quantifying brain metabolism from FDG-PET images into a probability of Alzheimer's dementia score. Hum Brain Mapp. (2020) 41:5–16. 10.1002/hbm.24783
    1. Hammoud DA, Boulougoura A, Papadakis GZ, Wang J, Dodd LE, Rupert A, et al. . Increased metabolic activity on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in human immunodeficiency virus-associated immune reconstitution inflammatory syndrome. Clin Infect Dis. (2019) 68:229–38. 10.1093/cid/ciy454
    1. Wallace M, Pyzalski R, Horejsh D, Brown C, Djavani M, Lu Y, et al. . Whole body positron emission tomography imaging of activated lymphoid tissues during acute simian-human immunodeficiency virus 89.6PD infection in rhesus macaques. Virology. (2000) 274:255–61. 10.1006/viro.2000.0479
    1. Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. . Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS. (2006) 20:985–93. 10.1097/01.aids.0000222070.52996.76
    1. Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, et al. . FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging. (2009) 36:640–7. 10.1007/s00259-008-1023-7
    1. Ankrah AO, Glaudemans A, Klein HC, Dierckx R, Sathekge M. The role of nuclear medicine in the staging and management of human immune deficiency virus infection and associated diseases. Nucl Med Mol Imaging. (2017) 51:127–39. 10.1007/s13139-016-0422-0
    1. Di Mascio M, Srinivasula S, Kim I, Duralde G, St Claire A, DeGrange P, et al. . Total body CD4+ T cell dynamics in treated and untreated SIV infection revealed by in vivo imaging. JCI Insight. (2018) 3:e97880. 10.1172/jci.insight.97880
    1. Schreiber-Stainthorp W, Sinharay S, Srinivasula S, Shah S, Wang J, Dodd L, et al. . Brain (18)F-FDG PET of SIV-infected macaques after treatment interruption or initiation. J Neuroinflammation. (2018) 15:207. 10.1186/s12974-018-1244-z
    1. Kung BT, Seraj SM, Zadeh MZ, Rojulpote C, Kothekar E, Ayubcha C, et al. . An update on the role of (18)F-FDG-PET/CT in major infectious and inflammatory diseases. Am J Nucl Med Mol Imaging. (2019) 9:255–73.
    1. Karashima R, Watanabe M, Imamura Y, Ida S, Baba Y, Iwagami S, et al. . Advantages of FDG-PET/CT over CT alone in the preoperative assessment of lymph node metastasis in patients with esophageal cancer. Surg Today. (2015) 45:471–7. 10.1007/s00595-014-0965-6
    1. Lebech AM, Gaardsting A, Loft A, Graff J, Markova E, Bertelsen AK, et al. . Whole-Body (18)F-FDG PET/CT is superior to CT as first-line diagnostic imaging in patients referred with serious nonspecific symptoms or signs of cancer: a randomized prospective study of 200 patients. J Nucl Med. (2017) 58:1058–64. 10.2967/jnumed.116.175380
    1. Okada M, Sato N, Ishii K, Matsumura K, Hosono M, Murakami T. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma. Radiographics. (2010) 30:939–57. 10.1148/rg.304095150
    1. Deleage C, Chan CN, Busman-Sahay K, Estes JD. Next-generation in situ hybridization approaches to define and quantify HIV and SIV reservoirs in tissue microenvironments. Retrovirology. (2018) 15:4. 10.1186/s12977-017-0387-9
    1. Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, et al. . Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci USA. (2015) 112:E1126–34. 10.1073/pnas.1414926112
    1. Zeng M, Southern PJ, Reilly CS, Beilman GJ, Chipman JG, Schacker TW, et al. . Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. (2012) 8:e1002437. 10.1371/journal.ppat.1002437
    1. Estes JD. Role of collagen deposition in lymphatic tissues and immune reconstruction during HIV-1 and SIV infections. Curr HIV/AIDS Rep. (2009) 6:29–35. 10.1007/s11904-009-0005-0
    1. Estes JD, Haase AT, Schacker TW. The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Semin Immunol. (2008) 20:181–6. 10.1016/j.smim.2008.04.002
    1. Abi-Jaoudeh N, Kruecker J, Kadoury S, Kobeiter H, Venkatesan AM, Levy E, et al. . Multimodality image fusion-guided procedures: technique, accuracy, and applications. Cardiovasc Intervent Radiol. (2012) 35:986–98. 10.1007/s00270-012-0446-5
    1. Venkatesan AM, Partanen A, Pulanic TK, Dreher MR, Fischer J, Zurawin RK, et al. . Magnetic resonance imaging-guided volumetric ablation of symptomatic leiomyomata: correlation of imaging with histology. J Vasc Interv Radiol. (2012) 23:786–94.e4. 10.1016/j.jvir.2012.02.015
    1. Krucker J, Xu S, Venkatesan A, Locklin JK, Amalou H, Glossop N, et al. . Clinical utility of real-time fusion guidance for biopsy and ablation. J Vasc Interv Radiol. (2011) 22:515–24. 10.1016/j.jvir.2010.10.033
    1. Venkatesan AM, Kadoury S, Abi-Jaoudeh N, Levy EB, Maass-Moreno R, Krucker J, et al. . Real-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation. Radiology. (2011) 260:848–56. 10.1148/radiol.11101985
    1. Wood BJ, Kruecker J, Abi-Jaoudeh N, Locklin JK, Levy E, Xu S, et al. . Navigation systems for ablation. J Vasc Interv Radiol. (2010) 21 (8 Suppl):S257–63. 10.1016/j.jvir.2010.05.003
    1. Sharma KV, Venkatesan AM, Swerdlow D, DaSilva D, Beck A, Jain N, et al. . Image-guided adrenal and renal biopsy. Tech Vasc Interv Radiol. (2010) 13:100–9. 10.1053/j.tvir.2010.02.005
    1. Trivedi H, Turkbey B, Rastinehad AR, Benjamin CJ, Bernardo M, Pohida T, et al. . Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer. Urology. (2012) 79:233–9. 10.1016/j.urology.2011.10.002
    1. Hoen B, Fournier I, Lacabaratz C, Burgard M, Charreau I, Chaix ML, et al. . Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J Acquir Immune Defic Syndr. (2005) 40:307–16. 10.1097/01.qai.0000182628.66713.31
    1. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, et al. . The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. (2012) 205:87–96. 10.1093/infdis/jir699
    1. Investigators ST, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, et al. . Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. (2013) 368:207–17. 10.1056/NEJMoa1110039
    1. Kilby JM, Goepfert PA, Miller AP, Gnann JW Jr, Sillers M, et al. . Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann Intern Med. (2000) 133:435–8. 10.7326/0003-4819-133-6-200009190-00011
    1. Piketty C, Weiss L, Assoumou L, Burgard M, Melard A, Ragnaud JM, et al. . A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol. (2010) 82:1819–28. 10.1002/jmv.21907
    1. Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, et al. . Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. (2014) 14:291–300. 10.1016/S1473-3099(13)70343-8
    1. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, et al. . AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis. (2010) 202:705–16. 10.1086/655468
    1. Strategies Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. . CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. (2006) 355:2283–96. 10.1056/NEJMoa062360
    1. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, et al. . Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. (2009) 23:1987–95. 10.1097/QAD.0b013e32832eb285
    1. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults Adolescents . Department of health human services Henry J. Kaiser family foundation. MMWR Recomm Rep. (1998) 47:43–82.
    1. Sorstedt E, Nilsson S, Blaxhult A, Gisslen M, Flamholc L, Sonnerborg A, et al. . Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels. BMC Infect Dis. (2016) 16:305. 10.1186/s12879-016-1628-6
    1. Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al. . Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. (2011) 66:1114–21. 10.1111/j.1398-9995.2011.02577.x
    1. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT, et al. . Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States, 2008. MMWR Recomm Rep. (2008) 57:1–12.
    1. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. . Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. (2019) 6:e259–68. 10.1016/S2352-3018(19)30052-9
    1. McManus WR, Bale MJ, Spindler J, Wiegand A, Musick A, Patro SC, et al. . HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. J Clin Invest. (2019) 129:4629–42. 10.1172/JCI126714
    1. Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. . Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. (2016) 375:2037–50. 10.1056/NEJMoa1608243
    1. Bartsch YC, Loos C, Rossignol E, Fajnzylber JM, Yuan D, Avihingsanon A, et al. . Viral rebound kinetics correlate with distinct HIV antibody features. mBio. (2021) 12:e00170–21. 10.1128/mBio.00170-21
    1. Castagna A, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, et al. . Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). J Antimicrob Chemother. (2019) 74:2039–46. 10.1093/jac/dkz138
    1. Le CN, Britto P, Brummel SS, Hoffman RM, Li JZ, Flynn PM, et al. . Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men. AIDS. (2019) 33:2149–56. 10.1097/QAD.0000000000002334
    1. Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. . The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. (2016) 30:343–53. 10.1097/01.aids.0000499516.66930.89
    1. Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, et al. . HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. (2016) 535:556–60. 10.1038/nature18929
    1. Wang CY, Wong WW, Tsai HC, Chen YH, Kuo BS, Lynn S, et al. . Effect of anti-CD4 antibody UB-421 on HIV-1 rebound after treatment interruption. N Engl J Med. (2019) 380:1535–45. 10.1056/NEJMoa1802264
    1. Eertink JJ, van de Brug T, Wiegers SE, Zwezerijnen GJC, Pfaehler EAG, Lugtenburg PJ, et al. . (18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. (2022) 49:932–42. 10.1007/s00259-021-05480-3
    1. Pfaehler E, Beukinga RJ, de Jong JR, Slart R, Slump CH, Dierckx R, et al. . Repeatability of (18) F-FDG PET radiomic features: a phantom study to explore sensitivity to image reconstruction settings, noise, and delineation method. Med Phys. (2019) 46:665–78. 10.1002/mp.13322
    1. Beckford-Vera DR, Flavell RR, Seo Y, Martinez-Ortiz E, Aslam M, Thanh C, et al. . First-in-human immunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody. Nat Commun. (2022) 13:1219. 10.1038/s41467-022-28727-5
    1. Henrich TJ, Jones T, Beckford-Vera D, Price PM, VanBrocklin HF. Total-Body PET imaging in infectious diseases. PET Clin. (2021) 16:89–97. 10.1016/j.cpet.2020.09.011
    1. Vansant G, Bruggemans A, Janssens J, Debyser Z. Block-And-Lock strategies to cure HIV infection. Viruses. (2020) 12:84. 10.3390/v12010084
    1. Yeh YJ, Ho YC. Shock-and-kill versus block-and-lock: targeting the fluctuating and heterogeneous HIV-1 gene expression. Proc Natl Acad Sci USA. (2021) 118:e2103692118. 10.1073/pnas.2103692118

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera